Esbriet, ofev approved to treat deadly lung disease

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

Approval was given to Esbriet (pirfenidone) and Ofev (nintedanib), the agency said in news releases on Wednesday.

Symptoms of IPF include shortness of breath, cough and difficulty engaging in everyday activities. Current treatments include supplemental oxygen, lung transplant or lung rehabilitation.

Esbriet, produced for Brisbane, Calif.-based InterMune Inc., was evaluated in three clinical trials involving 1,247 people with IPF. The most common side effects included nausea, rash, abdominal pain, upper , diarrhea, fatigue and headache.

Esbriet shouldn't be taken by people with severe liver problems or severe kidney disease, including people on dialysis, the FDA said.

Ofev, distributed by Boehringer Ingelheim of Ridgefield, Conn., was evaluated in clinical studies of 1,231 people with IPF. It's not recommended for people with moderate-to-severe liver problems or among women who may become pregnant. Since Ofev can cause birth defects, women who are able to become pregnant should use contraception for at least three months after the last dose of Ofev, the FDA said.

The most common side effects of Ofev included diarrhea, nausea, , vomiting, elevated liver enzymes, weight loss and loss of appetite.


Explore further

Impavido approved to treat tropical parasitic disease

More information: To learn more about idiopathic pulmonary fibrosis, visit the U.S. National Heart, Lung, and Blood Institute.

Copyright © 2014 HealthDay. All rights reserved.

Citation: Esbriet, ofev approved to treat deadly lung disease (2014, October 16) retrieved 22 October 2020 from https://medicalxpress.com/news/2014-10-esbriet-ofev-deadly-lung-disease.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments